xiaoyaxxxx
Lv1
50 积分
2021-10-21 加入
-
Biomarkers for monoclonal antibody targeting EGFR in NSCLC: Challenges, current status, and future perspectives
16天前
已关闭
-
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
27天前
已完结
-
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
1个月前
已完结
-
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making
1个月前
已完结
-
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
2个月前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
-
P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
1年前
已完结
-
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
1年前
已完结
-
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
1年前
已完结